CpG DNA induces stronger immune responses with less toxicity than other adjuvants

被引：232

作者：

Weeratna, RD

McCluskie, MJ

Xu, Y

Davis, HL

机构：

[1] Ottawa Hosp, Loeb Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada

[2] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada

[3] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada

[4] Univ Ottawa, Fac Hlth Sci, Sch Rehabil Sci, Ottawa, ON, Canada

[5] CpG ImmunoPharmaceut Inc, Wellesley, MA USA

来源：

VACCINE | 2000年 / 18卷 / 17期

基金：

英国医学研究理事会;

关键词：

adjuvant; vaccines; CpG DNA;

D O I：

10.1016/S0264-410X(99)00526-5

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The ability to augment protective immune responses with minimal side effects is quintessential for a good adjuvant. This study has compared various adjuvants that are used in animal research (Freund's complete and incomplete adjuvants, Titermax Gold), are licensed for human use (alum), or are in clinical testing for humans (monophosphoryl lipid, CpG DNA), for their ability to augment humoral responses to a model antigen (hepatitis B surface antigen) and for the degree of damage they caused in the injected muscle. According to the data, the adjuvant combination CpG DNA + alum had the greatest potential to augment immune responses with minimal side effects at the injection site. Evaluation of antibody isotypes indicated Th2 responses (no IgG2a) with all adjuvants except monophosphoryl lipid and CpG DNA, which gave mixed Th1/Th2 responses (IgG1 and were obtained with combinations of CpG DNA with other IgG2a). Strong Th1 responses (predominantly IgG2a) adjuvants. (C) 2000 Elsevier Science Ltd. All rights reserved.

引用

页码：1755 / 1762

页数：8

共 31 条

[1] Ballas ZK, 1996, J IMMUNOL, V157, P1840
[2] Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO
[3] 2-R
[4] Bomford R, 1998, DEV BIOL STAND, V92, P13
[5] BRODERSON JR, 1989, LAB ANIM SCI, V39, P400
[6] Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination
Carson, DA
Raz, E
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) : 1621 - 1622
[7] HEPATITIS-B VIRUS IMMUNOPATHOGENESIS
CHISARI, FV
FERRARI, C
[J]. ANNUAL REVIEW OF IMMUNOLOGY, 1995, 13 : 29 - 60
[8] CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
Chu, RS
Targoni, OS
Krieg, AM
Lehmann, PV
Harding, CV
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) : 1623 - 1631
[9] CONSTANT SL, 1999, ANNU REV IMMUNOL, V17, P255
[10] Immunology - Asthma: An epidemic in the absence of infection?
Cookson, WOCM
Moffatt, MF
[J]. SCIENCE, 1997, 275 (5296) : 41 - 42

← 1 2 3 4 →